A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Items 101–200 of 831
Alcoholic liver disease: A current molecular and clinical perspective
Ohashi, K., Pimienta, M., & Seki, E. (2018) · Liver Research · doi:10.1016/j.livres.2018.11.002 · Cited by 141
Vell, M. S., Loomba, R. S., Krishnan, A., Wangensteen, K. J., Trebicka, J., Creasy, K. T., Trautwein, C., Scorletti, E., Seeling, K. S., Hehl, L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.20222 · Cited by 137
Self-citationGeographical similarity and differences in the burden and genetic predisposition of NAFLD
Yip, T. C., Vilar‐Gomez, E., Petta, S., Yilmaz, Y., Wong, G. L., Adams, L. A., de Lédinghen, V., Sookoian, S., & Wong, V. W. (2023) · Hepatology · doi:10.1002/hep.32774 · Cited by 123
“[150,152] A recent study showed that a splice variant with an adenine insertion (rs72613567) in the HSD17B13 gene confers protection against chronic liver injury and mitigates progressive NASH among European American populations.[153] The protective effect of this variant was replicated in patients from diverse latitu…”
BackgroundArab, J. P., Roblero, J. P., Altamirano, J., Bessone, F., Chaves Araujo, R., Higuera-De la Tijera, F., Restrepo, J. C., Torre, A., Urzua, A., Simonetto, D. A., et al. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.04.005 · Cited by 119
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., Anstee, Q. M., & Workshop, O. B. O. T. P. O. T. A. (2019) · Hepatology · doi:10.1002/hep.30782 · Cited by 120
“The dynamic natural history of NAFLD.”
BackgroundInfluentialNAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
Stols-Gonçalves, D., Hovingh, G. K., Nieuwdorp, M., & Holleboom, A. G. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.08.008 · Cited by 118
Machine learning enables new insights into genetic contributions to liver fat accumulation
Haas, M. E., Pirruccello, J. P., Friedman, S. N., Wang, M., Emdin, C. A., Ajmera, V. H., Simon, T. G., Homburger, J. R., Guo, X., Budoff, M., et al. (2021) · Cell Genomics · doi:10.1016/j.xgen.2021.100066 · Cited by 118
Nabi, O., Lapidus, N., Boursier, J., de Lédinghen, V., Petit, J., Kab, S., Renuy, A., Zins, M., Lacombe, K., & Serfaty, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000329 · Cited by 127
“[11] Other genetic polymorphisms, such as HSD17B13 which is associated with the severity of NASH, should be tested in larger and longitudinal cohorts.[45] In our study, Asian ethnicity was strongly associated with lean NAFLD and was an independent predictor of advanced fibrosis.”
BackgroundAlcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study
Thursz, M. R., Kamath, P. S., Mathurin, P., Szabó, G., & Shah, V. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.041 · Cited by 117
Van Hout, C. V., Tachmazidou, I., Backman, J. D., Hoffman, J. X., Ye, B., Pandey, A. K., Gonzaga-Jauregui, C., Khalid, S., Liu, D., Banerjee, N., et al. (2019) · doi:10.1101/572347 · Cited by 110
Self-citationStickel, F., Lutz, P., Buch, S., Nischalke, H. D., Silva, I., Rausch, V., Fischer, J., Weiss, K. H., Gotthardt, D., Rosendahl, J., et al. (2020) · Hepatology · doi:10.1002/hep.30996 · Cited by 108
“The comparative survival advantage in women with alcohol-related cirrhosis is well documented,(31-33) and it has recently been shown that this may relate, at least in part, to a sex-variant interaction with rs738409:G in PNPLA3.”
BackgroundResultInfluentialToward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond
Krawczyk, M., Liebe, R., & Lammert, F. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.053 · Cited by 109
Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers
Liu, Z., Lin, C., Suo, C., Zhao, R., Li, J., Zhang, T., & Chen, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154955 · Cited by 131
Nonalcoholic Steatohepatitis After Liver Transplantation
Cotter, T. G., & Charlton, M. (2020) · Liver Transplantation · doi:10.1002/lt.25657 · Cited by 109
“(27) A recent study showed a loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis.(28) It remains to be seen the effect HSD17B13 has in NASH patients who undergo LT, but it would be reasonable to expect that there is incre…”
BackgroundChen, V. L., Oliveri, A., Miller, M. J., Wijarnpreecha, K., Du, X., Chen, Y., Cushing, K. C., Lok, A. S., & Speliotes, E. K. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.040 · Cited by 108
Alcohol‐Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study†
Szabó, G., Kamath, P. S., Shah, V. H., Thursz, M. R., Mathurin, P., Addolorato, G., Bataller, R. A., Burra, P., Castéra, L., Cortez‐Pinto, H., et al. (2019) · Hepatology · doi:10.1002/hep.30369 · Cited by 113
“Most recently, a splice variant encoding a lipid droplet protein was associated with a reduced risk of progression from steatosis to hepatitis.(19) Future studies will hopefully allow us to “individualise” care for patients with alcohol-related liver disease based on genetic predispositions, especially if “druggable”…”
BackgroundMiller, D. M., McCauley, K. F., & Dunham‐Snary, K. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70132 · Cited by 153
“In contrast, an insertion in 17-β hydroxysteroid dehydrogenase 13 ( HSD17B13 ) rs72613567 T>A appears protective, mitigating progression from steatohepatitis to HCC even among high-risk PNPLA3 carriers [133].”
Yang, J., Trépo, E., Nahon, P., Cao, Q., Moreno, C., Letouzé, E., Imbeaud, S., Bayard, Q., Gustot, T., Deviere, J., et al. (2019) · Hepatology · doi:10.1002/hep.30623 · Cited by 107
“239 dose-dependent manner.(20) Another study showed that the minor allele of HSD17B13 rs10433879, that is, in a close proxy with HSD17B13 rs72613567 (R2 = 0.”
BackgroundInfluentialIdentification of two pathways mediating protein targeting from ER to lipid droplets
Song, J., Mizrak, A., Lee, C.-W., Cicconet, M., Lai, Z. W., Tang, W.-C., Lu, C.-H., Mohr, S. E., Farese, R. V., & Walther, T. C. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00974-0 · Cited by 106
“, 2008) and HSD17B13 (Abul-Husn et al., 2018)] and lipodystrophy [PLIN1 (Gandotra et al.”
BackgroundInfluentialXian, Y., Weng, J., & Xu, F. L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001263 · Cited by 129
“HSD17B13 rs72613567 (TA) Reduce risk of NASH, but not steatosis.([33]) NA”
BackgroundInfluentialInsights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Arrese, M., Arab, J. P., Barrera, F., Kaufmann, B., Valenti, L., & Feldstein, A. E. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730927 · Cited by 103
Trépo, E., Caruso, S., Yang, J., Imbeaud, S., Couchy, G., Bayard, Q., Letouzé, É., Ganne‐Carrié, N., Moreno, C., Oussalah, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00603-3 · Cited by 112
Collin de l’Hortet, A., Takeishi, K., Guzman-Lepe, J., Morita, K., Achreja, A., Popovic, B., Wang, Y., Handa, K., Mittal, A., Meurs, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.017 · Cited by 101
“HSD17B13) have been associated to reduce risk of chronic liver failure(Abul-Husn et al., 2018).”
BackgroundLuukkonen, P. K., Tukiainen, T., Juuti, A., Sammalkorpi, H., Haridas, P. A. N., Niemelä, O., Arola, J., Orho-Melander, M., Hakkarainen, A., Kovanen, P. T., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132158 · Cited by 99
“Introduction A protein-truncating variant (rs72613567:TA), encoding the hepatic lipid droplet protein hydroxysteroid 17-β dehydrogenase 13 (HSD17B13), was recently reported to reduce risks of alcoholic and nonalcoholic cirrhosis (1, 2), fibrosis (1–3), and histologic signs of inflammation and ballooning (3).”
BackgroundResultInfluentialSchneider, C. V., Hamesch, K., Groß, A., Mandorfer, M., Moeller, L. S., Pereira, V. M., Pons, M., Kuca, P., Reichert, M., Benini, F., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.058 · Cited by 99
“In contrast, other studies reported a lower, but still significant, enrichment of Pi*MZ individuals in patients with ALD/NAFLD-associated cirrhosis or clinically significant portal hypertension as well as in patients who underwent liver transplantation.(10,11,19) Although the Pi*MZ status constitutes an undisputed ris…”
ResultSchwantes‐An, T., Darlay, R., Mathurin, P., Masson, S., Liangpunsakul, S., Mueller, S., Aithal, G. P., Eyer, F., Gleeson, D., Thompson, A., et al. (2021) · Hepatology · doi:10.1002/hep.31535 · Cited by 99
Israelsen, M., Juel, H. B., Detlefsen, S., Madsen, B. S., Rasmussen, D. N., Larsen, T. R., Kjærgaard, M., Fernandes Jensen, M. J., Stender, S., Hansen, T., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.11.038 · Cited by 98
Self-citationLiu, Z., Suo, C., Shi, O., Lin, C., Zhao, R., Yuan, H., Li, J., Zhang, T., & Chen, X. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.12.033 · Cited by 108
The CYTOLD and ERTOLD pathways for lipid droplet–protein targeting
Olarte, M.-J., Swanson, J. M. J., Walther, T. C., & Farese, R. V. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.08.007 · Cited by 98
Mak, L.-Y., Gane, E., Schwabe, C., Yoon, K. T., Heo, J., Scott, R., Lee, J.-H., Lee, J. I., Kweon, Y. O., Weltman, M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.11.025 · Cited by 98
Genome‐Wide Association Study of NAFLD Using Electronic Health Records
Fairfield, C. J., Drake, T. M., Pius, R., Bretherick, A. D., Campbell, A., Clark, D. W., Fallowfield, J. A., Hayward, C., Henderson, N. C., Joshi, P. K., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1805 · Cited by 97
Emerging role of aging in the progression of NAFLD to HCC
He, Y., Su, Y., Duan, C., Wang, S., He, W., Zhang, Y., An, X., & He, M. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101833 · Cited by 97
Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
Fang, T., Wang, H., Pan, X., Little, P. J., Xu, S., & Weng, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65044 · Cited by 114
“Human genetic research has shown that the splice variant of HSD17B13 (rs72613567: TA) prevented NAFLD development [128].”
BackgroundKanda, T., Goto, T., Hirotsu, Y., Masuzaki, R., Moriyama, M., & Omata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041525 · Cited by 94
“A meta-analysis of four randomized trials involving 134 NAFLD and NASH patients revealed that probiotic therapies can reduce AST, ALT, total cholesterol and TNF-α, and improve insulin resistance in these patients [52].”
BackgroundInfluentialPathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 116
Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity
Caruso, S., O’Brien, D. R., Cleary, S. P., Roberts, L. R., & Zucman‐Rossi, J. (2020) · Hepatology · doi:10.1002/hep.31394 · Cited by 103
Precision medicine in type 2 diabetes
Prasad, R. B., & Groop, L. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12859 · Cited by 91
Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder
Fromme, M., Schneider, C. V., Trautwein, C., Brunetti‐Pierri, N., & Strnad, P. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.022 · Cited by 101
Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions
Åberg, F., & Färkkilä, M. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1701443 · Cited by 87
Alferink, L. J. M., Radjabzadeh, D., Erler, N. S., Vojinović, D., Medina‐Gómez, C., Uitterlinden, A. G., de Knegt, R. J., Amin, N., Ikram, M. A., Janssen, H. L. A., et al. (2020) · Hepatology · doi:10.1002/hep.31417 · Cited by 93
Therapeutic opportunities for the treatment of NASH with genetically validated targets
Lindén, D., & Romeo, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.007 · Cited by 87
PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease
Dong, X. C. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00304 · Cited by 94
The metabolic basis of nonalcoholic steatohepatitis
Chakravarthy, M. V., & Neuschwander‐Tetri, B. A. (2020) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.112 · Cited by 87
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers
Whitfield, J. B., Schwantes-An, T.-H., Darlay, R., Aithal, G. P., Atkinson, S. R., Bataller, R., Botwin, G., Chalasani, N. P., Cordell, H. J., Daly, A. K., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.005 · Cited by 85
Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD
Vilarinho, S., Ajmera, V., Zheng, M., & Loomba, R. (2021) · Hepatology · doi:10.1002/hep.32047 · Cited by 85
Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis
Pickett‐Blakely, O., Young, K. A., & Carr, R. M. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.07.004 · Cited by 104
Nahon, P., Bamba‐Funck, J., Layese, R., Trépo, E., Zucman‐Rossi, J., Cagnot, C., Ganne‐Carrié, N., Chaffaut, C., Guyot, E., Ziol, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.11.003 · Cited by 86
Pathogenesis of Alcoholic Liver Disease
Kourkoumpetis, T., & Sood, G. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.09.006 · Cited by 84
Tanigawa, Y., Li, J., Justesen, J. M., Horn, H., Aguirre, M., DeBoever, C., Chang, C. C., Narasimhan, B., Lage, K., Hastie, T. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11953-9 · Cited by 89
Gellert‐Kristensen, H., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Stender, S. (2020) · Hepatology · doi:10.1002/hep.30799 · Cited by 80
Self-citationGenetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
Sookoian, S. C., Rotman, Y., & Valenti, L. V. C. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.052 · Cited by 93
Xanthakos, S. A., Ibrahim, S. H., Adams, K. H., Kohli, R., Sathya, P., Sundaram, S. S., Vos, M. B., Dhawan, A., Caprio, S., Behling, C. A., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001368 · Cited by 99
Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency
Fromme, M., Schneider, C. V., Pereira, V. M., Hamesch, K., Pons, M., Reichert, M., Benini, F., Ellis, P., Thorhauge, K. H., Mandorfer, M., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323729 · Cited by 83
PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Cherubini, A., Casirati, E., Tomasi, M., & Valenti, L. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2018418 · Cited by 79
“Among the other genetic risk variants for fatty liver disease, variation in HSD17B13 has recently been reported to influence the risk of both alcoholic and nonalcoholic liver diseases by interacting with PNPLA3 [36,37].”
BackgroundInfluentialInnes, H., Buch, S., Hutchinson, S., Guha, I. N., Morling, J. R., Barnes, E., Irving, W., Forrest, E., Pedergnana, V., Goldberg, D., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.014 · Cited by 79
Lean NAFLD: an underrecognized and challenging disorder in medicine
Maier, S., Wieland, A. C., Cree‐Green, M., Nadeau, K. J., Sullivan, S. A., Lanaspa, M. A., Johnson, R. J., & Jensen, T. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09621-1 · Cited by 85
Ghouse, J., Sveinbjörnsson, G., Vujković, M., Seidelin, A.-S., Gellert‐Kristensen, H., Ahlberg, G., Tragante, V., Rand, S. A., Brancale, J., Vilarinho, S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01720-y · Cited by 91
“Furthermore, the discovery of genetic variants linked to a reduced risk of cirrhosis may provide potential molecular targets for pharmacological intervention 6–9 .”
Self-citationLee, B., Lee, Y., Park, C., Rhee, E., Lee, W., Kim, N. H., Choi, K. M., Park, K., Choi, Y., Soo, B., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0010 · Cited by 86
Wang, Z., Zhu, S., Jia, Y., Wang, Y., Kubota, N., Fujiwara, N., Gordillo, R., Lewis, C., Zhu, M., Sharma, T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.014 · Cited by 72
Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics
Sookoian, S., & Pirola, C. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679920 · Cited by 70
Dongiovanni, P., Paolini, E., Corsini, A., Sirtori, C. R., & Ruscica, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13519 · Cited by 77
Genetic Insights for Drug Development in NAFLD
Eslam, M., & George, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.002 · Cited by 69
Combined alcoholic and non-alcoholic steatohepatitis
Wandji, L. C. N., Gnemmi, V., Mathurin, P., & Louvet, A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100101 · Cited by 78
Luukkonen, P. K., Sakuma, I., Gaspar, R. C., Mooring, M., Nasiri, A. R., Kahn, M., Zhang, X., Zhang, D., Sammalkorpi, H. E., Penttilä, A. K., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217543120 · Cited by 73
“The A variant encodes a prematurely truncated protein, consistent with loss-offunction (5).”
BackgroundResultInfluentialAntifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68
Grgurevic, I., Podrug, K., Mikolasevic, I., Kukla, M., Madir, A., & Tsochatzis, E. A. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/9181368 · Cited by 68
Santacroce, G., Gentile, A., Soriano, S., Novelli, A., Lenti, M. V., & Sabatino, A. D. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1124275 · Cited by 80
“Conversely, patients who carry variants in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13, rs72613567) and mitochondrial amidoxime-reducing component 1 (MARC1, rs2642438) are more protected than the general population (48, 49).”
BackgroundRole of HSD17B13 in the liver physiology and pathophysiology
Su, W., Mao, Z., Liu, Y., Zhang, X., Zhang, W., Gustafsson, J.-Α., & Guan, Y. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.014 · Cited by 85
Self-citationGenetics Is of the Essence to Face NAFLD
Meroni, M., Longo, M., Tria, G., & Dongiovanni, P. (2021) · Biomedicines · doi:10.3390/biomedicines9101359 · Cited by 73
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
Riazi, K., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · Nutrients · doi:10.3390/nu14214556 · Cited by 67
Sookoian, S., & Pirola, C. J. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0136 · Cited by 75
17‐Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury
Ma, Y., Brown, P. M., Lin, D. D., Ma, J., Feng, D., Belyaeva, O. V., Podszun, M. C., Roszik, J., Allen, J. N., Umarova, R., et al. (2020) · Hepatology · doi:10.1002/hep.31517 · Cited by 68
Kim, Y. J., Moon, S., Hwang, M. Y., Han, S., Jang, H.-M., Kong, J., Shin, D. M., Yoon, K., Kim, S., Lee, J.-E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34163-2 · Cited by 68
Self-citationCouteur, D. G. L., Ngu, M., Hunt, N. J., Brandon, A. E., Simpson, S. J., & Cogger, V. C. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01099-z · Cited by 89
Agbim, U., Carr, R. M., Pickett-Blakely, O., & Dagogo-Jack, S. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00349-x · Cited by 62
Amangurbanova, M., Huang, D. Q., & Loomba, R. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17292 · Cited by 59
Gutiérrez‐Cuevas, J., Lucano‐Landeros, S., López-Cifuentes, D., Santos, A., & Armendáriz‐Borunda, J. (2022) · Cancers · doi:10.3390/cancers15010023 · Cited by 68
“For example, the 17b-Hydroxysteroid dehydrogenase 13 (HSD17B13) rs72613567 variant leads to the synthesis of a truncated loss-of-function enzyme, and it was associated with a reduced risk of NASH and progressive liver damage (protects against ballooning degeneration, lobular inflammation, and fibrosis) [75,76].”
BackgroundDíaz, L. A., Arab, J. P., Idalsoaga, F. J., Perelli, J., Vega, J. A., Dirchwolf, M., Carreño, J., Samith, B., Valério, C. M., Moreira, R. O., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101903 · Cited by 86
“Conversely, other genetic variants, such as the protein-truncating hydroxysteroid 17-beta dehydrogenase 13 ( HSD17B13 ) variant, confer a protective effect against the development of MASLD [34].”
Nonalcoholic Fatty Liver Disease: A Global Perspective
Wong, W., & Chan, W. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.007 · Cited by 74
Ward, L. D., Tu, H.-C., Quenneville, C. B., Tsour, S., Flynn-Carroll, A. O., Parker, M. M., Deaton, A. M., Haslett, P. A. J., Lotta, L. A., Verweij, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24563-1 · Cited by 59
Self-citationNon-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
Bashir, A., Duseja, A. K., De, A., Mehta, M., & Tiwari, P. (2022) · Liver Research · doi:10.1016/j.livres.2022.05.002 · Cited by 69
Lipid mediators of liver injury in nonalcoholic fatty liver disease
Liangpunsakul, S., & Chalasani, N. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00170.2018 · Cited by 60
“Stearic acid: 200 M Oleic acid: 50–800 M Unsaturated fatty acids May have protective effect Eicosapentaenoic acid: 200 M (1, 3, 35, 38, 43) Contribute to fat removal from hepatocytes and improve insulin sensitivity Palmitoleic acid: 200–400 M”
BackgroundRosso, C., Caviglia, G. P., Birolo, G., Armandi, A., Pennisi, G., Pelusi, S., Younes, R., Liguori, A., Perez-Diaz-del-Campo, N., Nicolosi, A., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.024 · Cited by 59
Moore, J. B. (2019) · Proceedings of the Nutrition Society · doi:10.1017/s0029665119000570 · Cited by 59
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Takahashi, Y., Dungubat, E., Kusano, H., & Fukusato, T. (2023) · Biomedicines · doi:10.3390/biomedicines11102761 · Cited by 64
“Abul-Husn et al. [59] reported that the HSD17B13 rs72613567 T>TA variant was associated with a reduced risk of alcoholic liver disease and alcoholic and nonalcoholic cirrhosis.”
BackgroundHSD17B13: A Potential Therapeutic Target for NAFLD
Zhang, H., Su, W., Xu, H., Zhang, X., & Guan, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.824776 · Cited by 65
“28) for the HSD17B13 rs72613567:TA allele (Abul-Husn et al., 2018).”
Akbari, P., Sosina, O. A., Bovijn, J., Landheer, K., Nielsen, J. B., Kim, M., Aykul, S., De, T., Haas, M. E., Hindy, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32398-7 · Cited by 66
Self-citationStols-Gonçalves, D., Tristão, L. S., Henneman, P., & Nieuwdorp, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1151-4 · Cited by 55
Grimaudo, S., Bartesaghi, S., Rametta, R., Marra, F., Margherita Mancina, R., Pihlajamäki, J., Kakol‐Palm, D., Andréasson, A., Dongiovanni, P., Ludovica Fracanzani, A., et al. (2021) · Liver International · doi:10.1111/liv.14711 · Cited by 54
Global Epidemiological Impact of PNPLA3 I148M on Liver Disease
Kozlitina, J., & Sookoian, S. C. (2024) · Liver International · doi:10.1111/liv.16123 · Cited by 70
Self-citationBuch, S., Innes, H. A., Lutz, P. L., Nischalke, H. D., Marquardt, J. U., Fischer, J., Weiss, K. H., Rosendahl, J., Marot, A., Krawczyk, M. J., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327196 · Cited by 56
Genetic variants that associate with cirrhosis have pleiotropic effects on human traits
Chen, V. L., Chen, Y., Du, X., Handelman, S. K., & Speliotes, E. K. (2020) · Liver International · doi:10.1111/liv.14321 · Cited by 52
Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort
Wang, J., Conti, D. V., Bogumil, D. D., Sheng, X., Noureddin, M., Wilkens, L. R., Marchand, L. L., Rosen, H. R., Haiman, C. A., & Setiawan, V. W. (2021) · Hepatology Communications · doi:10.1002/hep4.1751 · Cited by 53
Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis
Ægidius, H. M., Veidal, S. S., Feigh, M., Hallenborg, P., Puglia, M., Pers, T. H., Vrang, N., Jelsing, J., Kornum, B. R., Blagoev, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58059-7 · Cited by 55
Whitfield, J. B., Masson, S., Liangpunsakul, S., Mueller, S., Aithal, G. P., Eyer, F., Gleeson, D., Thompson, A., Stickel, F., Soyka, M., et al. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000833 · Cited by 50
Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
Chrysavgis, L., Ztriva, E., Protopapas, A. A., Τζιόμαλος, Κ., & Cholongitas, Ε. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i42.6514 · Cited by 54
Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
Dorairaj, V., Sulaiman, S. A., Abu, N., & Murad, N. A. A. (2021) · Biomedicines · doi:10.3390/biomedicines10010015 · Cited by 59
“The latter SNP is protective and reduces NAFLD risk [115].”
BackgroundEpidemiology of Alcohol-Associated Liver Disease
Han, S., Yang, Z., Zhang, T., Ma, J., Chandler, K., & Liangpunsakul, S. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.03.009 · Cited by 56
Su, W., Wu, S., Yang, Y., Guo, Y., Zhang, H., Su, J., Chen, L., Mao, Z., Lan, R., Cao, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34299-1 · Cited by 49
Self-citation
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.